Tải bản đầy đủ - 0 (trang)
VII. COMPARISON OF INHIBITED STROMELYSIN TO OTHER MMPS

VII. COMPARISON OF INHIBITED STROMELYSIN TO OTHER MMPS

Tải bản đầy đủ - 0trang

inhibitor. Inhibitors binding to the primed subsites induced considerable

order in the regions 191 to 192 and 223 to 224. Most importantly, the

amide proton of His-223 formed a hydrogen bond to a carbonyl group of

the inhibitor. In addition to these changes residues remote from the

inhibitor, but near the binding sites showed increased mobility. These

results suggest that the rigidity of the S1 to S3 subsites are important for

distinguishing between ligands, while the flexible S1V to S3V subsites are

more accommodating to a broad range of residues. The flexibility of the

S1V subsite is in agreement with our observations. Interestingly, similar

studies on collagenase-1 with a hydroxymate inhibitor [19] bound to the

S1V to S3V subsites showed the analogous region to 220-226 of stromelysin1 was disordered in both the presence or absence of inhibitor. All these

results indicate that changes to mobility are complex and mostly unpre-



Figure 12 Catalytic mechanism of thermolysin and stromelysin-1. (A) The

mechanism of thermolysin [54]. (B) The mechanism of stromleysin-1 [10].

Equivalent residues to Tyr-157 and His-231 are not observed for stromelysin-1.

The proposed mechanism for collagenase-1 [53] is similar to stromelysin-1, but

also involves Asn-180 (equivalent to Asn-162 in stromelysin-1). This residue

cannot participate in stromelysin-1 due to an additional residue between Ala-165

and Asn-162. (Adapted from Ref. 10.)



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



dictable: however, such analyses may prove useful in supporting and

monitoring the presence of stabilizing interactions.

The mechanism proposed for fibroblast collagenase [53] and stromelysin-1 (10) is similar to that suggested for thermolysin [54] (Fig. 12). In

thermolysin the zinc ion ligates the carbonyl of the substrate and with Tyr157 and His-231 stabilizes the tetrahedral intermediate. In collagenase-1

and stromelysin-1, however, the stabilization of the carbonyl of the

substrate and the tetrahedal intermediate is by zinc alone. In thermolysin

the NH of the scissile bond is stabilized by a peptide carbonyl of Ala-182

and the side chain carbonyl of Asn-112. For collagenase-1 similar interactions by the peptide carbonyl of Ala-182 and the carbonyl of the side

chain of Asn-180 are suggested. For stromelysin-1, however, only the

carbonyl of Ala-165 would be involved in the stabilization of the NH of

the substrate; the equivalent Asn (Asn-162) is not involved as there is a

residue insertion in the stromelysin-1 sequence compared with the

collagenase-1 sequence. The proposed mechanisms of thermolysin, collagenase-1 and stromelysin-1 suggest that the Glu in the consensus

sequence HEXXH would promote the nucleophilic attack of water on

the scissile bond of the peptide substrate. The solution structure of

stromelysin-1 described here lacks the rigidity expected for the side chain

of this residue, Glu-202. In several members of the family of structures,

however, this side chain does approach a position that is consistent with

the mechanistic role of this residue.



VIII. CONCLUSION

This chapter has discussed the use of heteronuclear NMR and isotope

editing methods to determine the structure of protein complexes of

therapeutically important drug targets. NMR methodology continues

to develop with larger protein complexes being studied, and more

accurate structures being determined. Developments include deuteration

of proteins [1] to enhance relaxation properties, and experiment design,

for example, Transverse Relaxation Optimized Spectroscopy (TROSY)

[55], which takes advantage of favorable relaxation pathways thus

allowing proteins of at least 60 kDa to be studied; inclusion of residual

dipolar couplings as an orientation constraint in structure calculations

[56,57] are increasing the accuracy of solution structures; and combining

deuteration and TROSY experiments has allowed hydrogen bonds to be

directly observed and also included in structure calculations [58]. An



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



additional and powerful application of NMR spectroscopy is the method

of ‘‘NMR by SAR’’ developed by Fesik et al. [59], which has been applied

to finding new drug leads for stromelysin-1 [60]. NMR spectroscopy has

clearly become a powerful and essential tool in the design and development of novel drug leads.



REFERENCES

1. Clore GM, Gronenborn AM. Determining the structures of large proteins

and protein complexes by NMR. Trends Biotechnol 1998; 16:22 34.

2. Otting G, Wuăthrich K. Heteronuclear filters in two-dimensional [1H,1H]

NMR spectroscopy: combined use with isotope labelling for studies of

macromolecular conformation and intermolecular interactions. Q Rev

Biophys 1990; 23:39 – 96.

3. Cai M, Huang Y, Sakaguchi K, Clore GM, Gronenborn AM, Craigie R.

An efficient and cost-effective isotope labeling protocol for proteins

expressed in Escherichia coli. J Biomol NMR 1998; 11: 97 – 102.

4. Campbell ID, Downing AK. NMR of modular proteins. N Struct Biol 1998;

5(suppl): 496 – 499.

5. Gooley PR, Johnson BA, Marcy AI, Cuca GC, Salowe SP, Hagmann WK,

Esser CK, Springer JP. Secondary structure and zinc ligation of human

recombinant short-form stromelysin by multidimensional heteronuclear

NMR. Biochemistry 1993; 32:13098 – 13108.

6. Gooley PR, O’Connell JF, Marcy AI, Cuca GC, Salowe SP, Bush BL,

Hermes JD, Hagmann WK, Esser CK, Springer JP, Johnson BA. The

NMR structure of the inhibited catalytic domain of human stromelysin-1.

Nat Struct Biol 1994; 1:111 – 118.

7. Gooley PR, O’Connell JF, Marcy AI, Cuca GC, Hagmann WK, Caldwell

CG, Axel MG, Becker JW. Comparison of the structure of human

recombinant short form stromelysin by multidimensional heteronuclear

NMR and X-ray crystallography. J Biomol NMR 1996; 7:8 – 28.

8. Chapman KT, Kopka IE, Durette PI, Esser CK, Lanza TJ, IzquierdoMartin M, Niedzwiecki L, Chang B, Harrison RK, Kuo DW, Lin T-Y,

Stein RL, Hagmann WK. Inhibition of matrix metalloproteinases by

N-Carboxyalkyl peptides. J Med Chem 1993; 36:4293 – 4301.

9. Nagase H, Woessner JF Jr. Matrix metalloproteinases. J Biol Chem 1999;

274:2149 – 21494.

10. Becker JW, Marcy AI, Rokosz LL, Axel MG, Burbaum JJ, Fitzgerald

PMD, Cameron PM, Esser CK, Hagmann WK, Hermes JD, Springer JP.

Stromelysin-1: Three-dimensional structure of the inhibited catalytic

domain and of the C-truncated proenzyme. Prot Sci 1995; 4:1966 – 1976.



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



11. Li J, Brick P, O’Hare MC, Skarzynski T, Lloyd LF, Curry VA, Clark

IM, Bigg HF, Hazleman BL, Cawston TE, Blow DM. Structure of fulllength porcine synovial collagenase reveals a C-terminal domain containing a calcium-linked, four-bladed h-propellor. Structure 1995; 3:541

549.

12. Gomis-Ruăth FX, Gohlke U, Betz M, Knaăuper V, Murphy G, Lo´pez-Otı´ n

C, Bode W. The helping hand of collagenase-3 (MMP-13): 2.7 A˚ crystal

structure of its C-terminal haemopexin-like domain. J Mol Biol 1996;

264:556 566.

13. Gohlke U, Gomis-Ruăth FX, Crabbe T, Murphy G, Docherty AJP, Bode W.

The C-terminal (haemopexin-like) domain structure of human gelatinase A

(MMP-2): structural implications for its function. FEBS Lett 1996; 378:

126 – 130.

14. Bode W. A helping hand for collagenases: the hemopexin-like domain.

Structure 1995; 3:527 – 530.

15. Strongin AY, Collier I, Bannikov G, Marmer BL, Grant GA, Goldberg GI.

Mechanism of cell surface activation of 72-kDa type IV collagenase. J Biol

Chem 1995; 270:5331 – 5338.

16. de Souza SJ, Pereira HM, Jacchieri S, Brentani RR. Collagen/collagenase

interaction - does the enzyme mimic the conformation of its own substrate

FASEB J 1996; 10:927 930.

17. Bode W, Gomis-Ruăth FX, Stoăcker W. Astacins, serralysins, snake venom

and matrix metalloproteinases exhibit idential zinc-binding environments

(HEXXHXXGXXH and Met-turn) and topologies and should be

grouped into a common family, the ‘metzincins.’ FEBS Lett 1993; 331:

134 – 140.

18. Marcy AI, Eiberger LL, Harrison R, Chan HK, Hutchinson NI, Hagmann

WK, Cameron PM, Boulton DA, Hermes JD. Human fibroblast

stromelysin catalytic domain: expression, purification and characterization

of a C-terminally truncated form. Biochemistry 1991; 30:6476 – 6483.

19. Moy FJ, Pisano MR, Chanda PK, Urbano C, Killar LM, Sung M-L,

Powers R. Assignments, secondary structure and dynamics of the

inhibitor-free fragment of human fibroblast collagenase. J Biomol NMR

1997; 10:9 – 19.

20. Bartoki N, Winkler FK, Williams DH, D’Arcy A, Broadhurst MJ, Brown

PA, Johnson WH, Murray EJ. Structure of the catalytic domain of human

fibroblast collagenase complexed with an inhibitor. Nat Struct Biol 1994;

1:106 – 110.

21. Stams T, Spurlino JC, Smith DL, Wahl RC, Ho TF, Qoronfleh MW, Banks

TM. Structure of human neutrophil collagenase reveals large S1’ specificity

pocket. Nat Struct Biol 1994; 1:119 – 123.

22. Bode W, Reinemer P, Huber R, Kleine T, Schnierer S, Tschesche H. The Xray crystal structure of the catalytic domain of human neutrophil



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



23.



24.



25.



26.



27.



28.



29.



30.



31.



32.



33.



34.



collagenase inhibited by a substrate analogue reveals the essentials for

catalysis and specificity. EMBO J 1994; 13:1263 – 1269.

Lovejoy B, Cleasby A, Hassell AM, Longley K, Luther MA, Weigl D,

McGeehan G, McElroy AB, Drewry D, Lambert MH, Jordan SR. Structure

of the catalytic domain of fibroblast collagenase complexed with an

inhibitor. Science 1994; 263:375 – 377.

Moy FJ, Chanda PK, Chen JM, Cosmi S, Edris W, Skotnicki JS, Wilhelm J,

Powers P. NMR solution structure of the catalytic fragment of human

fibroblast collagenase complexed with a sulfonamide derivative of a

hydroxamic acid compound. Biochemistry 1999; 38:7085 – 7096.

Lovejoy B, Welch AR, Carr S, Luong C, Broka C, Hendricks RT, Campbell

JA, Walker KAM, Martin R, Van Watrt H, Browner MF. Crystal

structures of MMP-1 and MMP-13 reveal the structural basis for selectivity

of collagenase inhibitors. Nat Struct Biol 1999; 6:217 – 221.

Van Doren SR, Kurochkin AV, Hu W, Ye Q-Z, Johnson LL, Hupe DJ,

Zuiderweg ERP. Solution structure of the catalytic domain of human

stromelysin complexed with a hydrophobic inhibitor. Prot Sci 1995; 4:

2487 – 2498.

Browner MF, Smith WW, Castelhano AL. Matrilysin-inhibitor complexes:

common themes among metalloproteases. Biochemistry 1995; 34:6602 –

6610.

Morgunova E, Tuutila A, Bergmann U, Isupov M, Lindqvist Y, Schneider

G, Tryggvason K. Structure of human pro-matrix metalloproteinase-2:

activation mechanism revealed. Science 1999; 284: 1667 – 1670.

Muhandiram DR, Kay LE. Gradient-enhanced triple resonance threedimensional NMR experiments with improved sensitivity. J Magn Reson

1994; 103:203 216.

Loăhr F, Ruăterjans H. A triple resonance experiment for the sequential

assignment of backbone resonances in proteins. J Biomol NMR 1995;

6:189 – 197

Boucher W, Laue ED, Campbell SL, Domaille PJ. Improved 4D NMR

experiments for the assignment of backbone nuclei in 13C/15N labelled

proteins. J Biomol NMR 1992; 2:631 – 637.

Powers R, Gronenborn AM, Clore GM, Bax A. Three-dimensional tripleresonance NMR of 13C/15N-enriched proteins using constant-time evolution. J Magn Reson 1991; 94:209 – 213.

Kay LE, Xu G-Y, Singer AU, Muhandiram DR, Forman-Kay JD. A

gradient-enhanced HCCH-TOCSY experiment for recording side-chain 1H

and 13C correlations in H2O samples of proteins. J Magn Reson 1993;

101B:333 – 337.

Senn H, Werner B, Messerle BA, Weber C, Traber R, Wuăthrich K.

Stereospecic assignment of the methyl 1H NMR lines of valine and leucine



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



35.



36.



37.



38.



39.



40.



41.



42.



43.



44.



45.



46.



in polypeptides by nonrandom 13C labelling. FEBS Lett 1989; 249: 113 –

118.

Kuboniwa H, Grezesiek S, Delaglio F, Bax A. Measurement of HN-Ha J

couplings in calcium-free calmodulin using new 2D and 3D water-flip-back

methods. J Biomol NMR 1994; 4:871 – 878.

Archer SJ, Ikura M, Torchia DA, Bax A. An alternative 3D NMR

technique for correlating backbone 15N with side chain Hh resonances in

larger proteins. J Magn Reson 1991; 95:636 – 641.

Grzesiek S, Kuboniwa H, Hinck AP, Bax A. Mutiple-quantum line

narrowing for measurement of Ha-Hh J couplings in isotopically enriched

proteins. J Am Chem Soc 1995; 117:5312 – 5315.

Zhang O, Kay LE, Olivier JP, Forman-Kay JD. Backbone 1H and 15N

resonance assignments of the N-terminal SH3 domain of drk in folded and

unfolded states using enhanced sensitivity pulsed field gradient NMR

techniques. J Biol NMR 1994; 4:845 – 858.

Ikura M, Kay LE, Tsudin R, Bax A. Three-dimensional NOESYHMQC spectroscopy of a 13C-labelled protein. J Magn Reson 1990; 86:

204 – 209.

Vuister GW, Clore GM, Gronenborn AM, Powers R, Garrett DS, Tschudin

R, Bax A. Increased resolution and improved spectral quality in fourdimensional 13C/13C-separated HMQC-NOESY-HMQC spectra using

pulsed field gradients. J Magn Reson 1993; 101B:210 – 213.

Pelton JG, Torchia DA, Meadow ND, Roseman S. Tautomeric states of

the active-site histidines of phosphorylated and unphosphorylated IIIGlc,

a signal-transuding protein from Escherichia coli, using two-dimensional

heteronuclearNMR techniques. Prot Sci 1993; 2:543 – 558.

Petros AM, Kawai M, Luly JR, Fesik SW. Conformation of two nonimmunosuppressive FK506 analogs when bound to FKBP by isotopefiltered NMR. FEBS Lett 1992; 308:309 – 314.

Burgering M, Boelens R, Kaptein R. Observation of intersubunit NOEs in a

dimeric P22 Mnt repressor mutant by a time-shared [15N,13C] double halffilter technique. J Biomol NMR 1993; 3:709 714.

Guăntert P, Braun W, Billeter W, Wuăthrich K. Automated stereospecic 1H

NMR assignments and their impact on the precision of protein structure

determinations in solution. J Am Chem Soc 1989; 111:3997 4004.

Guăntert P, Braun W, Wuăthrich K. Ecient computation of three-dimensional protein structures in solution from nuclear magnetic resonance data

using the program DIANA and the supporting programs CALIBA,

HABAS and GLOMSA. J Mol Biol 1991; 217:517 530.

Guăntert P, Mumenthaler C, Wuăthrich K. Torsion angle dynamics for NMR

structure calculation with the new program DYANA. J Mol Biol 1997;

273:283 – 298.



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



47. Bruănger AT, Adams PD, Clore GM, DeLano WL, Gros P, GrosseKunstleve RW, Jiang J-S, Kuszewski J, Nilges M, Pannu NS, Read RJ, Rice

LM, Simonson T, Warren GL. Crystallography and NMR system: A new

software suite for macromolecular structure determination. Acta Cryst 1998;

d54:905 – 921.

48. Widmer H, Widmer A, Braun W. Extensive distance geometry calculations

with different noe calibrations - new criteria for structure selection applied to

sandostatin and BPTI. J Biomol NMR 1993; 3:307 324.

49. Schaumann T, Braun W, Wuăthrich K. The program FANTOM for energy

refinement of polypeptides and proteins using a Newton-Raphson minimizer

in torsion angle space. Biopolymers 1990; 29: 679 – 694.

50. Richardson JS. h-Sheet topology and the relatedness of proteins. Nature

1977; 268:495 – 500.

51. Stockman BJ, Waldon DJ, Gates JA, Schaill TA, Kloosterman DA, Mizsak

SA, Jacobsen EJ, Belonga KL, Mitchell MA, Mao B, Petke JD, Goodman

L, Powers EA, Ledbetter SR, Kaytes PS, Vogeli G, Marshall VP, Petzold

GL, Poorman RA. Solution structure of stromelysin complexed to

thiadiazole inhibitors. Prot Sci 1998; 7:2281 – 2286.

52. Yuan P, Marshall VP, Petzold GL, Poorman RA, Stockman BJ. Dynamics

of stromelysin/inhibitor interactions studied by 15N NMR relaxation

measurements: Comparison of ligand binding to the S1-S3 and S1’-S3’

subsites. J Biomol NMR 1999; 15:55 – 64.

53. Spurlino JC, Smallwood AM, Carlton DD, Banks TM, Vavra KJ, Johnson

JS, Cook ER, Falvo J, Wahl RC, Pulvino TA, Wendoloski JJ, Smith DL.

1.56 A˚ Structure of mature truncated human fibroblast collagenase. Proteins

1994; 19:98 – 109.

54. Mathews BW. Structural basis of the action of thermolysin and related zinc

peptidases. Acc Chem Res 1988; 21:333 340.

55. Pervushin K, Riek R, Wider G, Wuăthrich K. Attenuated T2 relaxation by

mutual cancellation of dipole-dipole coupling and chemical shift

anisotropy indicates an avenue to NMR structures of very large biological macromolecules in solution. Proc Natl Acad Sci 1997; 94:12366 –

12371.

56. Tjandra N, Bax A. Direct measurement of distances and angles in biomolecules by NMR in a dilute liquid crystalline medium. Science 1997;

278:1111 – 1114.

57. Olejniczak ET, Meadows RP, Wang H, Cai M, Nettesheim DG, Fesik SW.

Improved NMR structures of protein/ligand complexes using residual

dipolar couplings. J Am Chem Soc 1999; 121:9249 – 9250.

58. Cornilescu G, Hu J-S, Bax A. Identification of the hydrogen bonding

network in a protein by scalar couplings J Am Chem Soc 1999; 121:2949 –

2950.



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



59. Shuker SB, Hajduk PJ, Meadows RP, Fesik SW. Discovering high-affinity

ligands for proteins - SAR by NMR. Science 1996; 274:1531 – 1534.

60. Hajduk PJ, Sheppard G, Nettesheim DG, Olejniczak ET, Shuker SB,

Meadows RP, Steinman DH, Carrera GM, Marcotte PA, Severin J, Walter

K, Smith H, Gubbins E, Simmer R, Holzman TF, Morgan DW, Davidsen

SK, Summers JB, Fesik SW. Discovery of potent nonpeptide inhibitors of

stromelysin using SAR by NMR. J Am Chem Soc 1997; 119:5818 – 5827.

61. Schechter I, Berger A. On the size of the active site in proteases 1. Papain

Biochem. Biophys Res Commun 1967; 27:157 – 162.

62. Kraulis PJ. MOLSCRIPT: A Program to Produce Both Detailed and

Schematic Plots of Protein Structures. J Appl Crystallogr 1991; 24: 946 – 950.



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



4

Cannabinergics: Old and New

Therapeutic Possibilities

Alexandros Makriyannis

University of Connecticut, Storrs, Connecticut, U.S.A.



Andreas Goutopoulos

Serono Reproductive Biology Institute, Rockland, Massachusetts, U.S.A.



I.



INTRODUCTION



Cannabis sativa, one of the oldest plants farmed by man, has been known

for its medicinal properties for at least four millennia (Peters, 1999). The

psychoactive–euphoric effects of this plant, as well as its facile and wide

climatic range of cultivation, have rendered it a very popular recreational

drug. Today, cannabis, or marijuana, is still the focus of strong social,

legal, and medical controversy over its therapeutic utility.

Referenda in Arizona and California in 1997, and later, others in

eight additional states, aimed at legalizing marijuana cigarettes for medical

purposes. Two licensed, single-compound, cannabimimetic pharmaceuticals, Marinol (Dronabinol, delta-9-THC from Roxane Labs) and Cesamet

(Nabilone, developed at Eli Lilly, now in use in the United Kingdom), are

marketed for two purposes: to control the nausea and emesis produced by

cancer chemotherapy and to serve as appetite stimulants in AIDS-related

anorexia. In clinical trials with cancer chemotherapy patients, both these

agents have proven to be superior to conventional antiemetics, such as

perchlorperazine (Breivogel, 1998).

Beyond this relatively limited medical use of cannabimimetics, the

current, albeit long-delayed elucidation of their pharmacology is likely to

lead to a wide expansion of the clinical potential and significance of



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



these drugs. The oily, noncrystalline nature of the biologically active

terpenoid ingredients of Cannabis sativa contributed to the lag in understanding of cannabinoid biology. The main active ingredient, (–)-delta-9tetrahydrocannabinol (delta-9-THC), was isolated and identified only in

1964 (Mechoulam, 1967), over a hundred years after the isolation of many

important crystalline biologically active natural products, such as morphine and quinine. A second reason for the lack of progress in defining the

biology of cannabimimetics was the long-standing scientific misconception

that the cannabinoid-induced pharmacological actions are mediated by

perturbation of cellular membranes rather than through specific receptors.

This hypothesis was a deterrent in the pursuit of possible specific cannabinoid binding sites. Owing to their high lipophilicity, cannabinoids were

paralleled with general anesthetics in terms of their mechanism of action

(Paton, 1975). Although cannabinoids were found to clearly perturb membranes (Makriyannis, 1987), such effects were never proven to be directly

responsible for their biological activity.

The advent of synthetic cannabimimetics with a high degree of

enantioselectivity (Johnson, 1986; Little, 1988) paved the road for the

identification of specific cannabinoid binding sites in rat brain (Devane,

1988). This discovery marked the onset of a revolution in the understanding of cannabinoid biology.



II. CANNABINOID RECEPTORS

A. The CB1 Receptor

Definitive proof of the existence of the cannabinoid receptor came with

the isolation of the cDNA of a cannabinoid receptor from a rat cerebral

cortex cDNA library and its expression in Chinese hamster ovary

(CHO) cells (Matsuda, 1990). A year later, the corresponding human

receptor, named CB1, was cloned and found to share a 97.3% homology with the rat receptor (Gerard, 1991). The CB1 472 amino acid

sequence revealed (Matsuda, 1990; Gerard, 1991) that it is a member

of the G-protein-coupled receptors (GPCRs). Receptors of this family

are membrane embedded and consist of an extracellular N-terminus,

seven transmembrane helices interconnected with intra- and extracellular

loops, and an intracellular C-terminus. Bramblett et. al. (1995) constructed a model for CB1, using the known structure of bacteriorhodopsin as a starting point.



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



The sites involved in interactions with G proteins of the Gi/o family

are the third intracellular loop from the N-terminal side and the Cterminus (Howlett, 1998a). The C-terminus was found to bind with high

affinity to Gi and the synthetic C-terminus peptide was found to individually stimulate GTPgS binding to G protein and to inhibit adenylate

cyclase (Howlett, 1998b). Similarly with other GPCRs, CB1 is allosterically regulated by sodium ions. It has been shown that sodium ions affect

both ligand binding and signal transduction by inducing a receptor

conformational change (Houston, 1998). There is also evidence that an

interhelical H-bonding interaction between helix II Asp and helix VII Asn

is important for the stabilization of a receptor conformational state that

has high affinity for most cannabimimetic ligands (Tao, 1998), (Howlett,

1998a). Sodium ions presumably disrupt this H bond, and thus, result in a

different, low affinity, receptor state.

The CB1 receptor is coupled with Gi (Howlett, 1998a). CB1

activation leads to inhibition of adenylyl cyclase and, therefore, to reduction of cAMP levels. Many eukaryotic cells utilize cAMP as a

second messenger that activates the cAMP-dependent protein kinase A

(PKA), which in turn phosphorylates various proteins, regulating their

function. One of the cAMP-dependent cannabinoid effects is the

enhancement of voltage-sensitive, outwardly rectifying potassium channels, which occurs as a result of decreased phosphorylation of the K+

channel protein by PKA (Deadwyler, 1995). Besides Gi, CB1 is coupled

to Go (Howlett, 1999). Furthermore, apart from inhibition of adenylyl

cyclase, CB1 utilizes several additional effector systems (intracellular

mediators) involving Gi/o proteins: the inhibition of N-type Ca2+ channels (Mackie, 1992); the activation of mitogen-activated protein kinase

(MAP kinase) (Bouabula, 1995a); and the expression of immediate early

genes like Krox-24 (Bouabula, 1995b). Other cannabinoid-induced cellular effects include activation of inwardly-rectifying potassium channels

(Pertwee, 1997) and possibly the activation of phospholipases A, C, or D

(Felder, 1995).

Different G proteins or second messengers may be coupled to CB1

in different brain regions and may mediate different physiological effects

(Howlett, 1999). Utilization of diverse effector systems by CB1 may

explain how the response to cannabimimetics varies across different cell

types. Understanding which physiological responses are mediated by

each of the foregoing intracellular signaling systems is of great significance and may suggest new approaches for the design of selective

cannabimimetic agents.



Copyright 2004 by Marcel Dekker, Inc. All Rights Reserved.



Tài liệu bạn tìm kiếm đã sẵn sàng tải về

VII. COMPARISON OF INHIBITED STROMELYSIN TO OTHER MMPS

Tải bản đầy đủ ngay(0 tr)

×